BRAF and melanoma: This evidence suggests that targeting resistance mechanisms mediated by TKRs through ALW-II-41-27 or other multikinase inhibitors could represent an effective therapeutic strategy to overcome resistance in metastatic BRAF-mutant melanoma [161].